Viracta Therapeutics Inc To Discuss Nana-val For The Treatment Of Advanced Epstein-Barr Virus-Positive Solid Tumors Call Transcript

Apr 27, 2022 / 03:00PM GMT
Operator

Good morning, and welcome to the Viracta Therapeutics KOL Webinar. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Viracta website following the conclusion of the event. I'd now like to turn the call over to your host, Dr. Ivor Royston, President and Chief Executive Officer of Viracta Therapeutics. Please go ahead, Ivor.

Ivor Royston - Viracta Therapeutics, Inc. - CEO, President & Director

Okay. Thank you very much, (inaudible). It is my pleasure to be speaking with you at our KOL event today. We are pleased to partner with LifeSci Advisors for this event and what is an exciting time for Viracta.

Next slide. Before we begin, I'd like to remind you that certain statements in this presentation may be forward looking, and I invite you to visit our website to review our SEC filings and to read about the risks associated with such statements. For those of you who may be new to Viracta, the company lies at the intersection of virology and oncology, targeting virus-associated malignancies. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot